Takefumi Komiya, MD, PhD

Education

  • Fellow, Medical Oncology, National Cancer Institute/NIH, Bethesda, Maryland
  • Resident, Internal Medicine, Howard University Hospital, Washington, DC
  • Fellow, Post-Doctoral Research, Genetics Branch, National Cancer Institute/NIH, Bethesda, Maryland
  • Fellow, Thoracic Oncology, Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan
  • Fellow, Pulmonary Medicine, Pulmonary Department, Kawasaki Hospital, Japan
  • Resident, Internal Medicine, Kagoshima University, Japan
  • Doctor of Philosophy, Medicine, Kindai University School of Medicine
  • Doctor of Medicine, Kagoshima University Faculty of Medicine, Kagoshima, Japan

 

Accreditations/Associations

  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • International Association for Study of Lung Cancer

Honors/Awards

  • Conquer Cancer Foundation of ASCO Merit Award
  • Appreciation Award, Japan Society of Clinical Oncology, 2019
  • Appreciation Award presented by President, Japan Society of Lung Cancer

Publications/Presentations

  • Deshotels L, Chaaya G, Komiya T. An overview of lung and breast cancer using the national cancer database. Asian Pac J Cancer Prev. 2020;21:163-167.
  • Komiya T, et al. Brain metastasis as exclusion criteria in extensive-stage small cell lung cancer trials: a trend over five decades. J Cancer Metastasis Treat. 2020;6:4.
  • Komiya T, et al. Role of T0 status in overall survival for unresectable stage III non-small cell lung cancer: A NCDB analysis. Radiother Oncol 2020;148: 8-13.
  • Komiya T, et al. Recent trends in use of adjuvant chemotherapy in elderly stage II-III non-small cell lung cancer. Transl Lung Cancer Res 2020;9:1180-1186.
  • Guddati AK, Komiya T, et al. Impact of immunotherapy use in patients with stage IV pancreatic carcinoma. J Gastrointest Oncol 2020;11:654-662.
  • Komiya T, et al. Prognostic impact of single and multiple descriptors in pathologically staged T3N0M0 NSCLC. JTO Clin Res Rep. 2021;2:100111.
  • Takamori S, Komiya T. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis. Cancer Med. 2021;10:923-932
  • Komiya T, et al. Role of immunotherapy in stage IV large cell neuroendocrine carcinoma of the lung. Asian Pac J Cancer Prev. 2021;22:365-370.
  • Komiya T, et al. Role of thoracic radiation in extensive stage small cell lung cancer: A NCDB analysis. Med Oncol 2021. Published Online
  • Bardia A, Messersmith W, Komiya T, et al. Sacituzumab Govitecan, a Trop-2–Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial. Ann Oncol 2021. Published Online
  • Komiya T, et al. Role of T0 status in overall survival for unresectable stage III non-small cell lung cancer, 2020 ASCO annual (virtual) meeting (poster presentation), June 2020
  • Komiya T, et al. Role of immunotherapy in stage IV large cell neuroendocrine carcinoma of the lung, 2020 ASCO annual (virtual) meeting (poster presentation), June 2020
  • Santin A, Komiya T, et al. Sacituzumab govitecan in patients with previously treated metastatic endometrial cancer: results from a phase 1/2 study, 2020 ASCO annual (virtual) meeting (poster presentation), June 2020
  • Takamori S, Komiya T, et al. Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases. IASLC 2020 World Conference on Lung Cancer Singapore (Virtual) (poster presentation), Jan 2021.

find a provider doctorIcon-white.png